NewsAI-assisted

UCB Gains FDA Approval for Klygefa as First Dual-Binding Nanobody C5 Inhibitor

UCB's Klygefa becomes the first dual-binding nanobody C5 inhibitor approved in the US for generalized myasthenia gravis, delivered via subcutaneous autoinjector.

Vaibhavi M.
By Vaibhavi M.
Subject Matter Expert · Pharma Now
Nov 17, 20262 min read
UCB Gains FDA Approval for Klygefa as First Dual-Binding Nanobody C5 Inhibitor
AI-assisted reporting
Reviewed by Vaibhavi M., Subject Matter Expert · Pharma Now
60/ 100
Trust score
Moderate confidence

UCB's FDA approval of Klygefa for generalized myasthenia gravis establishes the first dual-binding nanobody C5 inhibitor on the US market, a regulatory milestone that carries immediate implications for fill-finish operations and combination product compliance teams managing subcutaneous autoinjector platforms.

Klygefa's once-weekly subcutaneous self-administration via autoinjector places it squarely within the combination product framework under 21 CFR Part 3, requiring manufacturers to address both drug and device constituent parts under a single regulatory strategy. For QA directors, that means integrated design controls, human factors validation, and container closure integrity testing aligned to the autoinjector's primary packaging configuration, a scope that extends well beyond standard biologics fill-finish.

The nanobody modality itself introduces distinct process considerations. Nanobodies, as single-domain antibody fragments, present a smaller molecular footprint than conventional monoclonal antibodies, which affects upstream expression systems, downstream purification train design, and formulation stability profiles. Teams benchmarking against existing C5 inhibitor programs will find limited direct precedent for dual-binding constructs at commercial scale, making ICH Q10 pharmaceutical quality system documentation and process validation packages particularly consequential during any pre-approval inspection cycle.

On the clinical side, Klygefa demonstrated rapid and sustained disease control in generalized myasthenia gravis, an indication where complement pathway inhibition has become an established mechanistic target. The approval adds a self-administration option to a therapeutic class previously dominated by intravenous infusion regimens, a shift that redistributes sterility assurance responsibility from clinical settings to device-dependent patient handling.

For regulatory affairs leads, the approval signals FDA's continued receptiveness to novel biologic modalities when supported by robust characterisation data, a read consistent with recent CDER guidance trajectories on complex biologics and combination products.

The commercial launch timeline and any post-approval commitments attached to the Klygefa approval will serve as the next measurable checkpoint for teams tracking UCB's combination product compliance posture.

Source: Media4Growth via Indian Pharma Post, 15 November 2026.

Read the original release ↗
TopicsNews
Vaibhavi M.
Written by
Vaibhavi M.
Subject Matter Expert · Pharma Now

Reporting on the science, business and regulation shaping the pharmaceutical industry.

Discussion

Loading discussion…

More from Pharma News

All stories →